CRVS — Corvus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $895.89m
- $680.66m
Corvus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Corvus Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Steven Cohen Reports 9.9% Passive Stake In Corvus Pharmaceuticals Inc As Of May 2
Corvus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Corvus Pharmaceuticals To Provide Business Update And Q1 2024 Financial Results On May 6, 2024
Brief: Corvus Pharmaceuticals Announces Initiation Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis
Corvus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-New York Community Bancorp, Ralph Lauren, Newell Brands
U.S. STOCKS ON THE MOVE-Take-Two Interactive, PepsiCo, Moderna
U.S. STOCKS ON THE MOVE-Blue Owl, Corvus Pharma, Nvidia
Corvus Pharma up as FDA grants orphan drug tag to blood cancer therapy
Brief: Corvus Pharmaceuticals Announces Orphan Drug Designation Granted To Soquelitinib For The Treatment Of T Cell Lymphoma
Brief: Corvus Pharmaceuticals Appoints Jeffrey Arcara As Chief Business Officer
Brief: Corvus Pharmaceuticals Presents New Interim Soquelitinib Data From Its Phase 1/1B T Cell Lymphoma Trial
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Corvus Pharmaceuticals Confirms Initiation of Phase 3 Registrational Study Trial For Soquelitinib In Peripheral T Cell Lymphoma Following Meeting With FDA
Corvus Pharma rises as FDA backs blood cancer drug study